• Skip to primary navigation
  • Skip to main content
  • Skip to footer

Bionor Holding AS

  • About us
  • Functional HIV cure
  • Products
  • Investors
  • News
  • Functional HIV cure
  • Vacc-4x vaccine
  • Vacc-C5 vaccine
  • Platform technology

News

News by the year

Vacc-CRX with neutralizing properties constitutes the 3 rd cornerstone of Bionor’s HIV program

Posted in Scientific 7.02.2019

Oslo, February 7, 2019 The recent Proof of Mechanism shown for Vacc-CRX demonstrates the dynamic properties of this product obstructing both of the well-known virus entry mechanisms CCR5 and CXCR4 […]


Bionor’s 3rd vaccine candidate, Vacc-CRX, Proof of Mechanism established

Posted in Scientific 23.01.2019

Oslo, January 23, 2019. Bionor is pleased to announce that Proof of Mechanism is established for our 3rd vaccine candidate, Vacc-CRX. This product aims to prevent binding between gp120 V3 […]


Bionor has acquired its 3rd HIV vaccine candidate, Vacc-CRX.

Posted in Investors 10.01.2019

Oslo, January 10, 2019 The acquisition is in the form of an exchange of patents and rights between Bionor and Immunor AS. During Bionor’s equity raise in December 2017, Bionor […]


  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 22
  • Go to Next Page »

Which year do you want to read news?

  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

    Footer

    • About us
    • Functional HIV cure
    • Products
    • Investors
    • News

    Bionor Holding AS
    Karenslysts Allé 6 – P.O. Box 4115 – NO-0217 Oslo – Norway
    [email protected]